论文部分内容阅读
目的探讨口服地塞米松治疗婴幼儿头颈部增生期血管瘤的临床效果及最佳剂量。方法婴幼儿头颈部增生期血管瘤患者90例,随机分为实验组(口服地塞米松治疗组)35例;对照组(平阳霉素注射治疗组30例,随诊观察组25例)55例,随诊3～20个月。结果口服地塞米松治疗组总有效率为88.6%(31/35),平阳霉素注射治疗组总有效率为90.0%(27/30),随诊观察组总有效率为64.0%(16/25),口服地塞米松治疗组和平阳霉素注射治疗组疗效相当,均优于随诊观察组(P<0.05),各组均未出现严重并发症。结论口服地塞米松治疗婴幼儿头颈部增生期血管瘤方法简单、疗效可靠、不良反应小,值得临床推广应用。
Objective To investigate the clinical effect and optimal dose of oral dexamethasone in the treatment of infantile head and neck proliferative hemangiomas. Methods 90 infants and young children with head and neck hyperplasia of hemangiomas were randomly divided into experimental group (oral dexamethasone treatment group) 35 cases; control group (pingyangmycin injection treatment group 30 cases, follow-up observation group 25 cases) Cases, followed up for 3 to 20 months. Results The total effective rate was 88.6% (31/35) in the oral dexamethasone group, 90.0% (27/30) in the Pingyangmycin injection group, and 64.0% in the observation group (64.0% 25), oral dexamethasone treatment group and pingyangmycin injection treatment group were comparable, were better than the observation group (P <0.05), no serious complications in each group. Conclusion oral dexamethasone treatment of infantile head and neck proliferative hemangioma is simple, reliable, less adverse reactions, it is worthy of clinical promotion and application.